Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice
Launched by SEUNG-JUNG PARK · Feb 5, 2018
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a procedure called rotational atherectomy, which is used to treat a condition known as coronary stenosis. This condition occurs when the arteries that supply blood to the heart become narrowed due to a buildup of plaque. The goal of the trial is to evaluate how effective and safe this procedure is when used in everyday clinical practice.
To participate in the trial, individuals must be at least 19 years old and have already received the rotational atherectomy treatment. They also need to agree to follow the study’s guidelines and provide written consent. Unfortunately, people with a life expectancy of less than one year are not eligible to join. Participants can expect to have regular check-ups and follow-ups as part of the study to monitor their health and the outcomes of the procedure. Overall, this research aims to improve understanding of how well rotational atherectomy works for patients with narrowed coronary arteries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥ 19 years old
- • Patients who received rotational atherectomy
- • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
- Exclusion Criteria:
- • Life expectancy \<1y
About Seung Jung Park
Seung-Jung Park is a distinguished clinical trial sponsor recognized for his commitment to advancing medical research and innovation. With a focus on cardiology and interventional procedures, he leads initiatives that aim to improve patient outcomes through rigorous clinical trials. His expertise in trial design and execution ensures adherence to the highest ethical standards and regulatory requirements. By fostering collaboration among multidisciplinary teams, Seung-Jung Park drives the development of cutting-edge therapies, contributing significantly to the scientific community and enhancing the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Daegu, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Pusan, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Bucheon, , Korea, Republic Of
Seongnam, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials